Journal article

Young Adult and Usual Adult Body Mass Index and Multiple Myeloma Risk: A Pooled Analysis in the International Multiple Myeloma Consortium (IMMC)

Brenda M Birmann, Gabriella Andreotti, Anneclaire J De Roos, Nicola J Camp, Brian CH Chiu, John J Spinelli, Nikolaus Becker, Veronique Benhaim-Luzon, Parveen Bhatti, Paolo Boffetta, Paul Brennan, Elizabeth E Brown, Pierluigi Cocco, Laura Costas, Wendy Cozen, Silvia de Sanjose, Lenka Foretova, Graham G Giles, Marc Maynadie, Kirsten Moysich Show all



Background: Multiple myeloma risk increases with higher adult body mass index (BMI). Emerging evidence also supports an association of young adult BMI with multiple myeloma. We undertook a pooled analysis of eight case-control studies to further evaluate anthropometric multiple myeloma risk factors, including young adult BMI.Methods: We conducted multivariable logistic regression analysis of usual adult anthropometric measures of 2,318 multiple myeloma cases and 9,609 controls, and of young adult BMI (age 25 or 30 years) for 1,164 cases and 3,629 controls.Results: In the pooled sample, multiple myeloma risk was positively associated with usual adult BMI; risk increased 9% per 5-kg/m2 increas..

View full abstract


Awarded by NCI

Awarded by American Cancer Society

Awarded by National Cancer Institute (SEER)

Awarded by Health Ministry of Spain

Awarded by Catalan Government

Awarded by Leukemia and Lymphoma Society

Awarded by European Commission

Awarded by Carlos III Institute of Health

Awarded by Marato TV3 Foundation

Awarded by International Agency for Research on Cancer

Awarded by MHCZ - DRO (MMCI)

Awarded by RECAMO

Awarded by Fondation de France (EpiLymph-France)

Awarded by Italian Association for Cancer Research (AIRC)

Awarded by Italian Ministry of Education, University and Research, PRIN programme

Awarded by German Federal Office for Radiation Protection


Funding Acknowledgements

Financial support for this study was provided by the NCI Intramural Program Division of Cancer Epidemiology and Genetics, and by NCI grants K07 CA115687 (to B.M. Birmann), R01 CA149445, R01 CA127435, P30 CA014089, R21CA198239, and R13 CA159842. B.M. Birmann was also supported in part by the American Cancer Society (RSG-11-020-01-CNE), and W. Cozen was supported in part by Federal funds from the National Cancer Institute (SEER): N01-CP-67010 SOW 16. Additional support was provided by Rio Hortega (CM13/00232), MV15/00025 and public grants from Health Ministry of Spain (PI11/01810 and PI14/01219) and the Catalan Government (2014SGR756). The Utah studies were supported by the Research Informatics Shared Resource, which in part is funded by NCI P30CA042014 and Leukemia and Lymphoma Society award 6067-09 (to N.J. Camp). EpiLymph was supported by European Commission 5th Framework Program (QLK4-CT-2000-00422); 6th Framework Program (FOOD-CT-2006-023103); Carlos III Institute of Health (FIS PI081555, RCESP C03/09, RTICESP C03/10, RTICRD06/0020/0095, CIBERESP, and European Regional Development Fund-ERDF); Marato TV3 Foundation (051210); International Agency for Research on Cancer (IARC-5111); MHCZ - DRO (MMCI, 00209805), RECAMO CZ.1.05/2.1.00/03.0101; Fondation de France (1999 008471; EpiLymph-France); Italian Association for Cancer Research (AIRC, Investigator Grant 11855); Italian Ministry of Education, University and Research, PRIN programme (2007WEJLZB, 20092ZELR2); the German Federal Office for Radiation Protection (StSch4261 and StSch4420; EpiLymph Germany); and the Health Research Board, Ireland. The collection of patients used in this publication was supported in part by the California Department of Health Services as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.